Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease

Clinical Neuropharmacology

Volumn 28, Issue 6, 2005, Pages 274-276

  Müller, Thomas ^a   Fowler, Brian ^b   Kuhn, Wilfried ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Levodopa; Parkinson disease; S adenosylmethionine

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; DOPA DECARBOXYLASE INHIBITOR; LEVODOPA; S ADENOSYLMETHIONINE; ANTIPARKINSON AGENT; METHIONINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HUMAN; LONG TERM CARE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SYNTHESIS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; METHIONINE; MIDDLE AGED; PARKINSON DISEASE; S-ADENOSYLMETHIONINE; TIME FACTORS;

EID: 33644875081     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000190800.87380.c7     Document Type: Article

References (16)

1. Benson R, Crowell B, Hill B, et al. The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance. Neurochem Res. 1993;18:325-330.
2. Miller JW, Shukitt-Hale B, Villalobos-Molina R, et al. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 1997;20:55-66.
3. Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol. 1997;145:580-585.
4. Müller T, Woitalla D, Hauptmann B, et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett. 2001;308:54-56.
5. Zhao WQ, Latinwo L, Liu XX, et al. L-Dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-Omethyltransferase. Exp Neurol. 2001;171:127-138.
6. Zhao WQ, Williams Z, Shepherd KR, et al. S-adenosyl-methionineinduced apoptosis in PC12 cells. J Neurosci Res. 2002;69:519-529.
7. Müller T, Woitalla D, Schulz D, et al. Tolcapone increases maximum concentration of levodopa. J Neural Transm. 2000;107:113-119.
8. Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav. 1992;43:423-431.
9. Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev. 2003;8:7-19.
10. Williams AL, Girard C, Jui D, et al. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med. 2005;28:132-139.
11. Müller T. Mood disorders in early Parkinson's disease. Curr Opin Psychiatry. 2004;17:191-196.
12. Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia. 2002;40:2257-2267.
13. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand. 2001;104:312-315.
14. Matsubara K, Aoyama K, Suno M, et al. N-methylation underlying Parkinson's disease. Neurotoxicol Teratol. 2002;24:593-598.
15. Charlton CG, Crowell B Jr. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism. Mol Chem Neuropathol. 1995;26:269-284.
16. Goetze O, Wieczorek J, Müller T, et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett. 2005;375:170-173.